January 29, 2013 at 09:32 AM EST
Pfizer Q4 net jumps on sale of nutrition business
Pfizer Inc.'s fourth-quarter profit more than quadrupled, despite competition from generic drugs hurting sales, because of a $4.8 billion gain from selling its nutrition business. The world's biggest drugmaker said Tuesday that its net income was $6.32 billion, or 85 cents per share, up from $1.44 billion, or 19 cents per share, a year earlier. Excluding one-time items, the Viagra maker would have had a profit of $3.51 billion, or 47 cents per share—3 cents more than analysts surveyed by FactSet were expecting. The New York-based company's stock rose 4 cents to $2688 in premarket trading. Revenue fell 7% to $15.1 billion, mainly due to generic competition to cholesterol blockbuster Lipitor. Analysts expected $14.35 billion. Lipitor, which had reigned as the world's top-selling drug ever for nearly a decade, got U.S. generic competition in December 2011 and now has generic rivals in many major markets. The drug had been bringing Pfizer nearly $11 billion a year before then, down from its peak of $13 billion a year. In the fourth quarter, Lipitor sales plunged 91% in the U.S. and 71% worldwide, to $584 million. A dozen other medicines also had lower sales due to generic competition. But key newer drugs had double-digit sales increases, including fibromyalgia and pain treatment Lyrica, at $1.13 billion, painkiller Celebrex at $750 million, and the Prevnar 13 vaccine against meningitis and other pneumococcal infections, at $993 million. Altogether, Pfizer's prescription drug revenue fell 9% in the quarter, to $12.89 billion. The animal health business, which Pfizer is planning to spin off, saw revenue increase 6 percent, to $1.17 billion. The consumer health business, which sells Centrum vitamins, had revenue jump 16%, to $936 million. Pfizer said this year it expects earnings per share of $2.20 to $2.30, excluding one-time items, and revenue of $56.2 billion to $58.2 billion. Analysts are expecting $2.28 per share and revenue of $57.55 billion. For the full year, net income was $14.57 billion, or $1.94 per share. That was down from $10.01 billion, or $1.27 per share, in 2011. Revenue totaled $58.99 billion, down 10 percent from $65.26 billion in 2011, before generic competition slashed sales of Lipitor and schizophrenia drug Geodon.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here